Andrew R Ruszkiewicz
Overview
Explore the profile of Andrew R Ruszkiewicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
645
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bedrikovetski S, Traeger L, Fitzsimmons T, Price T, Ruszkiewicz A, Vather R, et al.
Ann Surg Oncol
. 2023 Dec;
31(3):1681-1689.
PMID: 38071720
Background: The impact of RAS/BRAF mutation on primary response rates after total neoadjuvant therapy (TNT) in patients with advanced rectal cancer is unclear. The aim of this study was to...
2.
Mikaeel R, Symonds E, Kimber J, Smith E, Horsnell M, Uylaki W, et al.
Asia Pac J Clin Oncol
. 2020 Sep;
17(1):131-138.
PMID: 32885561
Background: Colorectal cancer (CRC) is rising in incidence in young adults, and this observation is currently unexplained. We investigated whether having a personal history of type 2 diabetes mellitus (T2D)...
3.
Chiam K, Mayne G, Watson D, Woodman R, Bright T, Michael M, et al.
Ann Surg Oncol
. 2018 Jul;
25(9):2731-2738.
PMID: 29987600
Background: Clinical trials report improved overall survival following neoadjuvant chemoradiotherapy in patients undergoing surgery for esophageal adenocarcinoma, with a 10-15% survival improvement. MicroRNAs (miRNAs) are small noncoding RNAs that are...
4.
Hoffmann R, Hebenstreit A, Game P, Ruszkiewicz A, Thompson S
ANZ J Surg
. 2017 Jan;
88(11):E797-E798.
PMID: 28116819
No abstract available.
5.
Young J, Price T, Moore J, Ruszkiewicz A
Pathol Res Pract
. 2016 Feb;
212(8):751-3.
PMID: 26839160
No abstract available.
6.
Thomas M, Hewett P, Ruszkiewicz A, Moore J
Asia Pac J Clin Oncol
. 2015 Oct;
11(4):343-51.
PMID: 26471980
Aim: In colorectal cancer (CRC), adjuvant therapy is offered on the basis of stage and attempts to identify factors to better target treatment have not been successful. Recent work suggested...
7.
Smith E, Palethorpe H, Ruszkiewicz A, Edwards S, Leach D, Underwood T, et al.
Dig Dis Sci
. 2015 Oct;
61(2):433-43.
PMID: 26467701
Background: Esophageal adenocarcinoma is a male-dominant disease, but the role of androgens is unclear. Aims: To examine the expression and clinical correlates of the androgen receptor (AR) and the androgen-responsive...
8.
Jorissen R, Christie M, Mouradov D, Sakthianandeswaren A, Li S, Love C, et al.
Br J Cancer
. 2015 Aug;
113(6):979-88.
PMID: 26305864
Background: APC mutations (APC-mt) occur in ∼70% of colorectal cancers (CRCs), but their relationship to prognosis is unclear. Methods: APC prognostic value was evaluated in 746 stage I-IV CRC patients,...
9.
Day F, Jorissen R, Lipton L, Mouradov D, Sakthianandeswaren A, Christie M, et al.
Clin Cancer Res
. 2013 May;
19(12):3285-96.
PMID: 23633456
Purpose: PIK3CA and PTEN mutations are prevalent in colorectal cancer and potential markers of response to mitogen-activated protein/extracellular signal-regulated kinase inhibitors and anti-EGF receptor antibody therapy. Relationships between phosphoinositide 3-kinase...
10.
Fleming N, Jorissen R, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, et al.
Cancer Res
. 2012 Nov;
73(2):725-35.
PMID: 23139211
Activation of the canonical TGF-β signaling pathway provides growth inhibitory signals in the normal intestinal epithelium. Colorectal cancers (CRCs) frequently harbor somatic mutations in the pathway members TGFBR2 and SMAD4,...